Screener / SEC EDGAR /CIK 0001704292 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Zai Lab Ltd ZLAB

Compare with peers Embed

ZLAB among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
+15.3%56th of 155 · median +10.5%
Net margin
-4.1%15.3%
-44.9%138th of 154 · median 6.8%
Return on equity
-5.2%18.5%
-35.2%126th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
-37.0%129th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
0.4531st of 108 · median 0.69

ZLAB and 9 peers, year by year

The 9 Health care companies closest to ZLAB in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthGross marginOperating marginNet marginFCF marginReturn on equityDebt / equity
ZLAB Zai Lab Ltd FY2025 $460.2M+15.0%-−49.9%−38.1%−34.5%−24.5%0.29
TWST Twist Bioscience Corp FY2025 $376.6M+20.3%-−36.2%−20.6%−20.1%−16.4%-
WGS GeneDx Holdings Corp. FY2025 $427.5M+40.0%69.7%−3.1%−4.9%3.3%−6.8%0.18
KRYS Krystal Biotech, Inc. FY2025 $389.1M+33.9%-41.5%52.6%48.5%16.8%-
ADMA Adma Biologics, Inc. FY2025 $510.2M+19.6%57.4%37.5%28.8%5.5%30.8%0.15
PRCT PROCEPT BioRobotics Corp FY2025 $308.1M+37.2%63.7%−33.7%−31.0%−18.9%−26.1%0.14
PTGX Protagonist Therapeutics, Inc FY2025 $46.0M−89.4%-−343.6%−282.8%121.9%−21.2%-
VCEL Vericel Corp FY2025 $276.3M+16.5%74.4%4.0%6.0%9.0%4.7%-
VCYT Veracyte, Inc. FY2025 $517.1M+16.0%70.1%11.2%12.8%24.5%5.1%-
RYTM Rhythm Pharmaceuticals, Inc. FY2025 $189.8M+45.8%-−101.2%−103.6%−61.5%−141.3%0.78

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2016 to FY2025 · 10-K XBRL

ZLABZai Lab Ltd
FY2018 revenue $129KFY2019 revenue $13.0MFY2020 revenue $49.0MFY2021 revenue $144.3MFY2022 revenue $215.0MFY2023 revenue $266.7MFY2024 revenue $399.0MFY2025 revenue $460.2M FY2020 net margin −549.3%FY2021 net margin −488.2%FY2022 net margin −206.1%FY2023 net margin −125.5%FY2024 net margin −64.4%FY2025 net margin −38.1% FY2016FY2025
Revenue$460.2M Growth+15.0% Net margin−38.1%
TWSTTwist Bioscience Corp
FY2017 revenue $10.8MFY2018 revenue $25.4MFY2019 revenue $54.4MFY2020 revenue $90.1MFY2021 revenue $132.3MFY2022 revenue $203.6MFY2023 revenue $245.1MFY2024 revenue $313.0MFY2025 revenue $376.6M FY2017 net margin −550.8%FY2018 net margin −280.2%FY2019 net margin −198.0%FY2020 net margin −155.3%FY2021 net margin −114.9%FY2022 net margin −107.0%FY2023 net margin −83.5%FY2024 net margin −66.7%FY2025 net margin −20.6% FY2016FY2025
Revenue$376.6M Growth+20.3% Net margin−20.6%
WGSGeneDx Holdings Corp.
FY2019 revenue $196.2MFY2020 revenue $179.3MFY2021 revenue $212.2MFY2022 revenue $234.7MFY2023 revenue $202.6MFY2024 revenue $305.4MFY2025 revenue $427.5M FY2019 net margin −15.1%FY2020 net margin −134.6%FY2021 net margin −115.6%FY2022 net margin −233.9%FY2023 net margin −86.8%FY2024 net margin −17.1%FY2025 net margin −4.9% FY2016FY2025
Revenue$427.5M Growth+40.0% Net margin−4.9%
KRYSKrystal Biotech, Inc.
FY2023 revenue $50.7MFY2024 revenue $290.5MFY2025 revenue $389.1M FY2023 net margin 21.6%FY2024 net margin 30.7%FY2025 net margin 52.6% FY2016FY2025
Revenue$389.1M Growth+33.9% Net margin52.6%
ADMAAdma Biologics, Inc.
FY2016 revenue $10.7MFY2017 revenue $22.8MFY2018 revenue $17.0MFY2019 revenue $29.3MFY2020 revenue $42.2MFY2021 revenue $80.9MFY2022 revenue $154.1MFY2023 revenue $258.2MFY2024 revenue $426.5MFY2025 revenue $510.2M FY2016 net margin −183.1%FY2017 net margin −192.3%FY2018 net margin −387.1%FY2019 net margin −164.5%FY2020 net margin −179.4%FY2021 net margin −88.5%FY2022 net margin −42.8%FY2023 net margin −10.9%FY2024 net margin 46.4%FY2025 net margin 28.8% FY2016FY2025
Revenue$510.2M Growth+19.6% Net margin28.8%
PRCTPROCEPT BioRobotics Corp
FY2020 revenue $7.7MFY2021 revenue $34.5MFY2022 revenue $75.0MFY2023 revenue $136.2MFY2024 revenue $224.5MFY2025 revenue $308.1M FY2020 net margin −687.0%FY2021 net margin −173.6%FY2022 net margin −116.2%FY2023 net margin −77.8%FY2024 net margin −40.7%FY2025 net margin −31.0% FY2016FY2025
Revenue$308.1M Growth+37.2% Net margin−31.0%
PTGXProtagonist Therapeutics, Inc
FY2017 revenue $20.1MFY2018 revenue $30.9MFY2019 revenue $231KFY2020 revenue $28.6MFY2021 revenue $27.4MFY2022 revenue $26.6MFY2023 revenue $60.0MFY2024 revenue $434.4MFY2025 revenue $46.0M FY2017 net margin −184.2%FY2018 net margin −125.9%FY2020 net margin −231.1%FY2021 net margin −458.9%FY2022 net margin −479.3%FY2023 net margin −131.6%FY2024 net margin 63.3%FY2025 net margin −282.8% FY2016FY2025
Revenue$46.0M Growth−89.4% Net margin−282.8%
VCELVericel Corp
FY2016 revenue $54.4MFY2017 revenue $63.9MFY2018 revenue $90.9MFY2019 revenue $117.8MFY2020 revenue $124.2MFY2021 revenue $156.2MFY2022 revenue $164.4MFY2023 revenue $197.5MFY2024 revenue $237.2MFY2025 revenue $276.3M FY2016 net margin −36.0%FY2017 net margin −27.0%FY2018 net margin −9.0%FY2019 net margin −8.2%FY2020 net margin 2.3%FY2021 net margin −4.8%FY2022 net margin −10.2%FY2023 net margin −1.6%FY2024 net margin 4.4%FY2025 net margin 6.0% FY2016FY2025
Revenue$276.3M Growth+16.5% Net margin6.0%
VCYTVeracyte, Inc.
FY2016 revenue $65.1MFY2017 revenue $72.0MFY2018 revenue $92.0MFY2019 revenue $120.4MFY2020 revenue $117.5MFY2021 revenue $219.5MFY2022 revenue $296.5MFY2023 revenue $361.1MFY2024 revenue $445.8MFY2025 revenue $517.1M FY2016 net margin −48.2%FY2017 net margin −43.1%FY2018 net margin −25.0%FY2019 net margin −10.5%FY2020 net margin −29.7%FY2021 net margin −34.4%FY2022 net margin −12.3%FY2023 net margin −20.6%FY2024 net margin 5.4%FY2025 net margin 12.8% FY2016FY2025
Revenue$517.1M Growth+16.0% Net margin12.8%
RYTMRhythm Pharmaceuticals, Inc.
FY2021 revenue $3.2MFY2022 revenue $23.6MFY2023 revenue $77.4MFY2024 revenue $130.1MFY2025 revenue $189.8M FY2022 net margin −766.2%FY2023 net margin −238.5%FY2024 net margin −200.3%FY2025 net margin −103.6% FY2016FY2025
Revenue$189.8M Growth+45.8% Net margin−103.6%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2016 to FY2025

Revenue as reported in the 10-K.

$0 $517.1M FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TWST: -, $10.8M, $25.4M, $54.4M, $90.1M, $132.3M, $203.6M, $245.1M, $313.0M, $376.6M TWST WGS: -, -, -, $196.2M, $179.3M, $212.2M, $234.7M, $202.6M, $305.4M, $427.5M WGS KRYS: -, -, -, -, -, $0, $0, $50.7M, $290.5M, $389.1M KRYS ADMA: $10.7M, $22.8M, $17.0M, $29.3M, $42.2M, $80.9M, $154.1M, $258.2M, $426.5M, $510.2M ADMA PRCT: -, -, -, -, $7.7M, $34.5M, $75.0M, $136.2M, $224.5M, $308.1M PRCT PTGX: -, $20.1M, $30.9M, $231K, $28.6M, $27.4M, $26.6M, $60.0M, $434.4M, $46.0M PTGX VCEL: $54.4M, $63.9M, $90.9M, $117.8M, $124.2M, $156.2M, $164.4M, $197.5M, $237.2M, $276.3M VCEL VCYT: $65.1M, $72.0M, $92.0M, $120.4M, $117.5M, $219.5M, $296.5M, $361.1M, $445.8M, $517.1M VCYT RYTM: $0, $0, $0, $0, $0, $3.2M, $23.6M, $77.4M, $130.1M, $189.8M RYTM ZLAB: -, -, $129K, $13.0M, $49.0M, $144.3M, $215.0M, $266.7M, $399.0M, $460.2M ZLAB
ZLAB is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from $0 to $517.1M. A gap is a year with no number. A ring marks where a line starts: ZLAB, TWST, WGS, KRYS, PRCT, PTGX have no earlier 10-K here.

Sales growth, FY2016 to FY2025

Revenue against the fiscal year before.

−99.3% +649% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TWST: -, -, +136%, +114%, +65.7%, +46.9%, +53.8%, +20.4%, +27.7%, +20.3% TWST WGS: -, -, -, -, −8.6%, +18.3%, +10.6%, −13.7%, +50.8%, +40.0% WGS KRYS: -, -, -, -, -, -, -, -, +473%, +33.9% KRYS ADMA: +48.5%, +113%, −25.4%, +72.8%, +43.9%, +91.7%, +90.4%, +67.6%, +65.2%, +19.6% ADMA PRCT: -, -, -, -, -, +347%, +118%, +81.6%, +64.8%, +37.2% PRCT PTGX: -, -, +54.1%, −99.3%, n/m, −4.4%, −2.8%, +126%, +624%, −89.4% PTGX VCEL: +6.3%, +15.4%, +44.8%, +29.7%, +3.5%, +25.5%, +6.9%, +20.7%, +20.1%, +16.5% VCEL VCYT: +31.5%, +10.6%, +27.9%, +30.8%, −2.4%, +86.8%, +35.1%, +21.8%, +23.5%, +16.0% VCYT RYTM: -, -, -, -, -, -, +649%, +228%, +68.1%, +45.8% RYTM ZLAB: -, -, -, n/m, +277%, +194%, +47.6%, +25.4%, +49.1%, +15.0% ZLAB
ZLAB is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −99.3% to +649%. A gap is a year with no number. A ring marks where a line starts: ZLAB, TWST, WGS, KRYS, PRCT, PTGX, RYTM have no earlier 10-K here.

Gross margin, FY2016 to FY2025

Gross profit / revenue.

−148.4% 74.4% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 WGS: -, -, -, 42.2%, 2.2%, −7.8%, −11.4%, 44.4%, 63.6%, 69.7% WGS ADMA: 40.3%, −28.1%, −148.4%, -, −45.2%, 1.4%, 22.9%, 34.4%, 51.5%, 57.4% ADMA PRCT: -, -, -, -, −16.3%, 46.0%, 49.4%, 52.2%, 61.1%, 63.7% PRCT VCEL: 47.9%, 52.5%, 64.6%, 68.1%, 67.8%, 67.9%, 66.8%, 68.6%, 72.6%, 74.4% VCEL VCYT: -, -, -, -, -, -, 59.2%, 63.6%, 66.9%, 70.1% VCYT ZLAB: -, -, 66.6%, -, -, -, -, -, -, - ZLAB
ZLAB is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −148.4% to 74.4%. A gap is a year with no number. A ring marks where a line starts: ZLAB, WGS, PRCT, VCYT have no earlier 10-K here.
CompanyFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
ZLAB Dec --66.6%-------
TWST Sep ----------
WGS Dec ---42.2%2.2%−7.8%−11.4%44.4%63.6%69.7%
KRYS Dec ----------
ADMA Dec 40.3%−28.1%−148.4%-−45.2%1.4%22.9%34.4%51.5%57.4%
PRCT Dec ----−16.3%46.0%49.4%52.2%61.1%63.7%
PTGX Dec ----------
VCEL Dec 47.9%52.5%64.6%68.1%67.8%67.9%66.8%68.6%72.6%74.4%
VCYT Dec ------59.2%63.6%66.9%70.1%
RYTM Dec ----------
Peer median----−7.0%23.7%49.4%52.2%63.6%69.7%

Operating margin, FY2016 to FY2025

Operating income / revenue.

−757.9% 58.2% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TWST: -, −543.2%, −277.5%, −200.1%, −155.5%, −115.4%, −115.3%, −88.6%, −70.6%, −36.2% TWST WGS: -, -, -, −15.5%, −134.9%, −210.3%, −284.5%, −89.2%, −7.6%, −3.1% WGS KRYS: -, -, -, -, -, -, -, −216.2%, 22.6%, 41.5% KRYS ADMA: −162.6%, −172.7%, −354.9%, −141.1%, −153.8%, −72.1%, −25.5%, 8.4%, 32.6%, 37.5% ADMA PRCT: -, -, -, -, −619.4%, −157.1%, −107.6%, −80.2%, −43.0%, −33.7% PRCT PTGX: -, −188.9%, −136.7%, n/m, −225.4%, −460.0%, −494.2%, −156.1%, 58.2%, −343.6% PTGX VCEL: −35.4%, −23.4%, −4.3%, −9.5%, 1.9%, −5.0%, −10.4%, −3.3%, 1.9%, 4.0% VCEL VCYT: −44.3%, −36.9%, −24.2%, −12.6%, −30.1%, −37.3%, −13.9%, −23.8%, 3.6%, 11.2% VCYT RYTM: -, -, -, -, -, n/m, −757.9%, −238.1%, −204.0%, −101.2% RYTM ZLAB: -, -, n/m, n/m, −616.4%, −485.1%, −188.0%, −137.4%, −70.7%, −49.9% ZLAB
ZLAB is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −757.9% to 58.2%. A gap is a year with no number. A ring marks where a line starts: ZLAB, TWST, WGS, KRYS, PRCT, PTGX, RYTM have no earlier 10-K here.

Net margin, FY2016 to FY2025

Net income / revenue.

−766.2% 63.3% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TWST: -, −550.8%, −280.2%, −198.0%, −155.3%, −114.9%, −107.0%, −83.5%, −66.7%, −20.6% TWST WGS: -, -, -, −15.1%, −134.6%, −115.6%, −233.9%, −86.8%, −17.1%, −4.9% WGS KRYS: -, -, -, -, -, -, -, 21.6%, 30.7%, 52.6% KRYS ADMA: −183.1%, −192.3%, −387.1%, −164.5%, −179.4%, −88.5%, −42.8%, −10.9%, 46.4%, 28.8% ADMA PRCT: -, -, -, -, −687.0%, −173.6%, −116.2%, −77.8%, −40.7%, −31.0% PRCT PTGX: -, −184.2%, −125.9%, n/m, −231.1%, −458.9%, −479.3%, −131.6%, 63.3%, −282.8% PTGX VCEL: −36.0%, −27.0%, −9.0%, −8.2%, 2.3%, −4.8%, −10.2%, −1.6%, 4.4%, 6.0% VCEL VCYT: −48.2%, −43.1%, −25.0%, −10.5%, −29.7%, −34.4%, −12.3%, −20.6%, 5.4%, 12.8% VCYT RYTM: -, -, -, -, -, n/m, −766.2%, −238.5%, −200.3%, −103.6% RYTM ZLAB: -, -, n/m, n/m, −549.3%, −488.2%, −206.1%, −125.5%, −64.4%, −38.1% ZLAB
ZLAB is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −766.2% to 63.3%. A gap is a year with no number. A ring marks where a line starts: ZLAB, TWST, WGS, KRYS, PRCT, PTGX, RYTM have no earlier 10-K here.

Free cash flow, FY2016 to FY2025

Cash from operations minus capital spending.

−$567.5M $188.9M FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TWST: -, −$57.9M, −$69.9M, −$102.7M, −$152.1M, −$139.3M, −$226.2M, −$170.3M, −$69.2M, −$75.6M TWST WGS: -, -, -, −$30.7M, −$117.2M, −$199.8M, −$326.3M, −$185.4M, −$34.0M, $14.3M WGS KRYS: −$1.3M, −$4.1M, −$11.7M, −$25.1M, −$40.9M, −$116.3M, −$153.5M, −$100.6M, $119.2M, $188.9M KRYS ADMA: −$18.3M, −$39.9M, −$64.8M, −$80.0M, −$114.7M, −$125.9M, −$73.4M, $4.0M, $110.4M, $27.8M ADMA PRCT: -, -, -, -, −$48.6M, −$57.9M, −$83.0M, −$133.2M, −$103.6M, −$58.3M PRCT PTGX: −$30.3M, $3.2M, −$50.4M, −$42.5M, −$73.0M, −$109.0M, −$108.9M, −$70.8M, $182.8M, $56.1M PTGX VCEL: −$21.3M, −$14.7M, −$3.1M, −$9.8M, $14.9M, $21.1M, $10.1M, $15.3M, −$5.8M, $24.7M VCEL VCYT: −$32.2M, −$25.7M, −$15.4M, −$6.0M, −$12.5M, −$37.0M, −$1.0M, $34.3M, $63.8M, $126.6M VCYT RYTM: −$24.3M, −$29.6M, −$62.8M, −$126.1M, −$122.2M, −$146.4M, −$173.7M, −$136.2M, −$113.9M, −$116.6M RYTM ZLAB: −$34.4M, −$41.5M, −$107.6M, −$197.0M, −$226.2M, −$567.5M, −$392.2M, −$205.4M, −$220.5M, −$158.9M ZLAB
ZLAB is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$567.5M to $188.9M. A gap is a year with no number. A ring marks where a line starts: TWST, WGS, PRCT have no earlier 10-K here.

FCF margin, FY2016 to FY2025

Free cash flow / revenue.

−734.9% 121.9% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TWST: -, −537.7%, −274.7%, −188.8%, −168.8%, −105.3%, −111.1%, −69.5%, −22.1%, −20.1% TWST WGS: -, -, -, −15.6%, −65.4%, −94.2%, −139.0%, −91.5%, −11.1%, 3.3% WGS KRYS: -, -, -, -, -, -, -, −198.4%, 41.0%, 48.5% KRYS ADMA: −172.1%, −175.5%, −381.4%, −272.6%, −271.7%, −155.5%, −47.6%, 1.6%, 25.9%, 5.5% ADMA PRCT: -, -, -, -, −629.5%, −168.0%, −110.7%, −97.8%, −46.2%, −18.9% PRCT PTGX: -, 16.0%, −163.1%, n/m, −254.8%, −398.3%, −409.8%, −118.1%, 42.1%, 121.9% PTGX VCEL: −39.2%, −23.0%, −3.4%, −8.3%, 12.0%, 13.5%, 6.1%, 7.7%, −2.4%, 9.0% VCEL VCYT: −49.5%, −35.7%, −16.7%, −5.0%, −10.7%, −16.9%, −0.3%, 9.5%, 14.3%, 24.5% VCYT RYTM: -, -, -, -, -, n/m, −734.9%, −175.9%, −87.5%, −61.5% RYTM ZLAB: -, -, n/m, n/m, −462.0%, −393.3%, −182.4%, −77.0%, −55.3%, −34.5% ZLAB
ZLAB is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −734.9% to 121.9%. A gap is a year with no number. A ring marks where a line starts: ZLAB, TWST, WGS, KRYS, PRCT, PTGX, RYTM have no earlier 10-K here.

Return on equity, FY2016 to FY2025

Net income / shareholders' equity at the year end.

−184.3% 56.6% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TWST: -, n/m, n/m, −70.8%, −41.6%, −26.2%, −27.6%, −32.8%, −44.2%, −16.4% TWST WGS: -, -, -, n/m, n/m, −63.2%, n/m, −77.1%, −21.3%, −6.8% WGS KRYS: n/m, −16.0%, −9.6%, −9.4%, −11.0%, −11.7%, −26.8%, 1.4%, 9.4%, 16.8% KRYS ADMA: n/m, −108.5%, n/m, −184.3%, −85.8%, −50.8%, −43.4%, −20.9%, 56.6%, 30.8% ADMA PRCT: -, -, -, -, n/m, −22.4%, −44.2%, −37.7%, −22.7%, −26.1% PRCT PTGX: −42.5%, −30.6%, −34.6%, −96.5%, −23.7%, −41.8%, −59.1%, −23.5%, 40.8%, −21.2% PTGX VCEL: −79.2%, −76.7%, −8.0%, −8.7%, 2.1%, −4.4%, −8.7%, −1.4%, 3.5%, 4.7% VCEL VCYT: −52.6%, −83.3%, −28.8%, −5.3%, −8.3%, −6.9%, −3.4%, −7.1%, 2.1%, 5.1% VCYT RYTM: n/m, −23.3%, −30.1%, −50.1%, −80.5%, −24.5%, −68.5%, −108.8%, n/m, −141.3% RYTM ZLAB: n/m, −21.4%, −55.4%, −66.2%, −23.0%, −51.1%, −42.4%, −42.0%, −30.6%, −24.5% ZLAB
ZLAB is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −184.3% to 56.6%. A gap is a year with no number. A ring marks where a line starts: ZLAB, TWST, WGS, KRYS, ADMA, PRCT, RYTM have no earlier 10-K here.

Debt / equity, FY2016 to FY2025

Total debt / shareholders' equity at the year end.

0.00 5.05 FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TWST: -, -, n/m, 0.05, 0.01, -, -, -, -, - TWST WGS: -, -, -, -, n/m, 0.03, 0.04, 0.25, 0.23, 0.18 WGS ADMA: n/m, 0.07, 0.14, 0.00, 1.05, -, -, -, 0.21, 0.15 ADMA PRCT: -, -, -, -, n/m, 0.19, 0.26, 0.18, 0.13, 0.14 PRCT PTGX: -, -, -, 0.12, -, -, -, -, -, - PTGX VCEL: 0.38, 0.75, -, -, -, -, -, -, -, - VCEL VCYT: 0.42, 0.67, 0.32, 0.00, 0.00, 0.00, -, -, -, - VCYT RYTM: -, -, -, -, -, -, -, 0.63, 5.05, 0.78 RYTM ZLAB: -, -, 0.01, 0.02, -, -, -, 0.00, 0.16, 0.29 ZLAB
ZLAB is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.00 to 5.05. A gap is a year with no number. A ring marks where a line starts: ZLAB, TWST, WGS, ADMA, PRCT, PTGX, RYTM have no earlier 10-K here.
CompanyFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
ZLAB Dec --0.010.02---0.000.160.29
TWST Sep --n/m0.050.01-----
WGS Dec ----n/m0.030.040.250.230.18
KRYS Dec ----------
ADMA Dec n/m0.070.140.001.05---0.210.15
PRCT Dec ----n/m0.190.260.180.130.14
PTGX Dec ---0.12------
VCEL Dec 0.380.75--------
VCYT Dec 0.420.670.320.000.000.00----
RYTM Dec -------0.635.050.78
Peer median-0.67-0.030.010.03-0.250.220.16

EPS (diluted), FY2016 to FY2025

Diluted earnings per share, on today's share count after splits.

−$264056.00 $6.84 FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 TWST: -, −$24.49, −$25.51, −$3.92, −$3.57, −$3.15, −$4.04, −$3.60, −$3.60, −$1.30 TWST WGS: -, -, -, −$264056.00, −$47036.00, −$2.27, −$53.63, −$7.23, −$1.94, −$0.73 WGS KRYS: −$1.31, −$1.48, −$0.97, −$1.20, −$1.71, −$3.13, −$5.49, $0.39, $3.00, $6.84 KRYS ADMA: −$1.61, −$1.91, −$1.45, −$0.89, −$0.88, −$0.51, −$0.33, −$0.13, $0.81, $0.60 ADMA PRCT: -, -, -, -, −$14.47, −$3.63, −$1.96, −$2.24, −$1.75, −$1.72 PRCT PTGX: −$5.80, −$2.09, −$1.74, −$2.98, −$1.92, −$2.71, −$2.60, −$1.39, $4.23, −$2.05 PTGX VCEL: −$1.18, −$0.52, −$0.20, −$0.22, $0.06, −$0.16, −$0.35, −$0.07, $0.20, $0.32 VCEL VCYT: −$1.09, −$0.91, −$0.62, −$0.27, −$0.66, −$1.11, −$0.51, −$1.02, $0.31, $0.82 VCYT RYTM: −$2.85, −$2.83, −$2.39, −$3.86, −$3.04, −$1.40, −$3.47, −$3.20, −$4.34, −$3.11 RYTM ZLAB: −$3.97, −$2.32, −$2.64, −$3.03, −$0.35, −$0.76, −$0.46, −$0.35, −$0.26, −$0.16 ZLAB
ZLAB is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$264056.00 to $6.84. A gap is a year with no number. A ring marks where a line starts: TWST, WGS, PRCT have no earlier 10-K here.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out ZLAB and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: ZLAB's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ZLAB/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.